Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion
of cancer therapies and the short-and long-term quality of life. Anthracyclines are currently …

Background: Cancer therapy–induced cardiomyopathy (CCM) is associated with cumulative
drug exposures and preexisting cardiovascular disorders. These parameters incompletely …

Background Troponin changes over time have been suggested to allow for an early
diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin …

In the field of cardio-oncology, it is well recognised that despite the benefits of chemotherapy
in treating and possibly curing cancer, it can cause catastrophic damage to bystander …

Despite the known cardiotoxic effects of doxorubicin and other anthracyclines, no evidence-
based guidelines exist for the surveillance and prevention of chemotherapy-induced …

Anthracycline cardiotoxicity remains a serious problem in paediatric and adult cancer
survivors, and the advancement of cardio-oncology is a necessary step for an effective care …

Current oncologic treatments have brought a strong reduction in mortality in cancer patients.
However, the cancer therapy-related cardiovascular complications, in particular chemo …

Background Cancer patients receiving chemotherapy have an increased risk of
cardiovascular complications. This limits the widespread use of lifesaving therapies, often …

Breast cancer treatments have evolved over the past decades, although several widely used
treatments have adverse cardiac effects. Radiotherapy generally improves the survival of …